《生命科学》 2022, 34(7): 815-820

SLC7A11在胰腺癌中的研究进展

李青芸^1,2 , 刘晓雯^1,2 , 向凤怡^1,2 , 王栎清^1,2,* , 谭　潇^1,2,*

¹三峡大学肿瘤微环境与免疫治疗湖北省重点实验室，宜昌 433002 ²三峡大学医学院，宜昌 433002

摘　要：

胰腺癌是发病隐匿且恶性程度极高的消化系统肿瘤，尽管目前的治疗策略取得了较大的进展，但胰腺癌的转移、复发、耐药仍是患者预后不良的主要原因。因此，寻找特异性分子靶标是当下胰腺癌治疗的关键性任务。溶质载体家族7 成员11 (solute carrier family 7 member 11, SLC7A11/xCT) 为一种氨基酸转运蛋白，通过介导胱氨酸摄取促进谷胱甘肽的合成，保护细胞免受氧化应激的损伤，在抑制氧化反应和维持氧化应激条件下的细胞存活中发挥关键作用。最近研究发现，SLC7A11 在胰腺癌中高表达，与胰腺癌的生长、转移、侵袭、耐药以及治疗密切相关，是胰腺癌新的潜在治疗靶点。该文重点介绍了SLC7A11 在胰腺癌中的功能以及作为治疗靶点的最新研究进展，为胰腺癌的诊断和靶向治疗提供新的思路。

 

通讯作者：王栎清 , Email:wangyueqing@ctgu.edu.cn 谭　潇 , Email:xiao-tan@ctgu.edu.cn

Research progress of SLC7A11 in pancreatic cancer

LI Qing-Yun^1,2 , LIU Xiao-Wen^1,2 , XIANG Feng-Yi^1,2 , WANG Yue-Qing^1,2,* , TAN Xiao^1,2,*

¹Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang 443003, China ²Medical College, China Three Gorges University, Yichang 443003, China

Abstract:

Pancreatic cancer is an insidious and highly malignant tumor of the digestive system. Although the current treatment strategies have made great progress, the metastasis, recurrence, and drug resistance of pancreatic cancer are still the primary reasons for the poor prognosis of patients. Therefore, identifying specific molecular targets is a key task in the treatment of pancreatic cancer. Solute carrier family 7 member 11 (SLC7A11/xCT) is an amino acid transporter that promotes the synthesis of glutathione by mediating cystine uptake and protects cells from oxidative stress. SLC7A11 plays an important role in inhibiting oxidative reactions and maintaining cell survival under oxidative stress. SLC7A11, recently identified as a potential therapeutic target for pancreatic cancer, is overexpressed in pancreatic cancer. In addition, it is closely associated with the growth, metastasis, invasion, drug resistance. This review focuses on the function of SLC7A11 in pancreatic cancer and the latest research progress as a therapeutic target providing new option for the diagnosis and targeted therapy of pancreatic cancer.

Communication Author：WANG Yue-Qing , Email:wangyueqing@ctgu.edu.cn TAN Xiao , Email:xiao-tan@ctgu.edu.cn